Compounds > lenalidomide
Page last updated: 2024-09-05

lenalidomide and Duncan Disease

lenalidomide has been researched along with Duncan Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Fukushima, H; Honda, A; Imadome, KI; Iwasaki, A; Jona, M; Kishino, Y; Kurokawa, M; Maki, H; Morita, K; Nishikawa, M; Ushiku, T; Yatomi, Y; Yoshida, M1
Au-Yeung, R; Hwang, YY; Kwong, YL; Lau, HP1
Dondero, R; Francis, SM; Liu, Z; Tang, T; Taylor, CA; Thompson, JE; Zheng, Q1
Degen, L; Juskevicius, D; Läubli, H; Rochlitz, C; Stenner-Liewen, F; Tzankov, A1
Nand, S; Portell, C1

Other Studies

5 other study(ies) available for lenalidomide and Duncan Disease

ArticleYear
Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma.
    International journal of hematology, 2023, Volume: 117, Issue:5

    Topics: Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immunomodulating Agents; Lenalidomide; Lymphohistiocytosis, Hemophagocytic; Lymphoproliferative Disorders; Multiple Myeloma

2023
Complete response of age-related Epstein-Barr virus-associated polymorphic nodal lymphoproliferative disease of plasmacytic type to low-dose lenalidomide.
    Annals of hematology, 2018, Volume: 97, Issue:2

    Topics: Aged, 80 and over; Aging; Antigens, CD; Epstein-Barr Virus Infections; Humans; Immunocompromised Host; Lenalidomide; Lymph Nodes; Lymphoproliferative Disorders; Male; Plasma Cells; Positron Emission Tomography Computed Tomography; Thalidomide

2018
SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2014, Volume: 22, Issue:9

    Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Translation Initiation Factor 5A; Humans; Lenalidomide; Lymphoproliferative Disorders; Mice; Nanoparticles; Neoplasm Transplantation; Peptide Initiation Factors; Polyethyleneimine; Pyrazines; RNA-Binding Proteins; RNA, Small Interfering; Thalidomide; Xenograft Model Antitumor Assays

2014
Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:4

    Topics: Adult; B-Lymphocytes; Biopsy; Epstein-Barr Virus Infections; Female; Genomics; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Lenalidomide; Lymphoproliferative Disorders; Remission Induction; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome

2016
Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder.
    Blood, 2008, Apr-15, Volume: 111, Issue:8

    Topics: Drug Resistance; Fatal Outcome; Female; Humans; Immunologic Factors; Kidney Transplantation; Lenalidomide; Lymphoproliferative Disorders; Middle Aged; T-Lymphocytes; Thalidomide

2008